- Home
- NXTC vs LYRA Comparison
NXTC vs LYRA Comparison
Compare NXTC & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- LYRA
- Stock Information
- Founded
- NXTC 2015
- LYRA 2005
- Country
- NXTC United States
- LYRA United States
- Employees
- NXTC N/A
- LYRA N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- LYRA Medical/Dental Instruments
- Sector
- NXTC Health Care
- LYRA Health Care
- Exchange
- NXTC Nasdaq
- LYRA Nasdaq
- Market Cap
- NXTC 13.9M
- LYRA 15.0M
- IPO Year
- NXTC 2019
- LYRA 2020
- Fundamental
- Price
- NXTC $6.17
- LYRA $7.95
- Analyst Decision
- NXTC Strong Buy
- LYRA Buy
- Analyst Count
- NXTC 3
- LYRA 2
- Target Price
- NXTC $33.00
- LYRA $16.00
- AVG Volume (30 Days)
- NXTC 299.6K
- LYRA 91.5K
- Earning Date
- NXTC 08-04-2025
- LYRA 08-13-2025
- Dividend Yield
- NXTC N/A
- LYRA N/A
- EPS Growth
- NXTC N/A
- LYRA N/A
- EPS
- NXTC N/A
- LYRA N/A
- Revenue
- NXTC N/A
- LYRA $1,185,000.00
- Revenue This Year
- NXTC N/A
- LYRA N/A
- Revenue Next Year
- NXTC N/A
- LYRA $139.18
- P/E Ratio
- NXTC N/A
- LYRA N/A
- Revenue Growth
- NXTC N/A
- LYRA N/A
- 52 Week Low
- NXTC $2.69
- LYRA $3.81
- 52 Week High
- NXTC $20.76
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- NXTC 62.21
- LYRA 41.08
- Support Level
- NXTC $4.75
- LYRA $7.77
- Resistance Level
- NXTC $5.23
- LYRA $8.67
- Average True Range (ATR)
- NXTC 0.56
- LYRA 0.45
- MACD
- NXTC 0.10
- LYRA -0.03
- Stochastic Oscillator
- NXTC 86.74
- LYRA 11.32
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.